Metacognitive Therapy for Depression: A 3-Year Follow-Up Study Assessing Recovery, Relapse, Work Force Participation, and Quality of Life.
depression
long-term follow-up
metacognition
metacognitive therapy
quality of life
recovery
relapse prevention
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
10
2019
accepted:
09
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
A major challenge in the treatment of depression has been high relapse rates following treatment. The current study reports results from a 3-year follow-up of patients treated with metacognitive therapy (MCT). Thirty-four of the 39 patients enrolled in the original study attended assessment (participation rate of 87%). There were large reductions in symptoms of depression, anxiety, interpersonal problems, and worry, as well as metacognitive beliefs. Three patients fulfilled diagnostic criteria for axis-I disorders: one with depression and two with generalized anxiety disorder. Sixty percent had not experienced any new depressive episodes in the 3-year follow-up period, and the static relapse rates were low (11-15%). Recovery rates ranged from 69 to 97% depending upon the four different criteria used. Nevertheless, 26% had sought out treatment for depression or other psychological difficulties. Most patients (70%) had experienced negative life events in the follow-up period, but these events did not influence current depression severity. Return to work outcomes were encouraging, as eight out of 13 patients that had been on benefits were no longer receiving benefits. Life satisfaction ratings showed mean scores around 70 (on a 0-100 scale) and showed a moderate to strong negative correlation with depression severity. In conclusion, MCT appears to be promising with respect to long-term effect. Randomized controlled trials should investigate if the long-term effect of MCT surpasses that of other evidence-based treatments for depression.
Identifiants
pubmed: 31920902
doi: 10.3389/fpsyg.2019.02908
pmc: PMC6936246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2908Informations de copyright
Copyright © 2019 Solem, Kennair, Hagen, Havnen, Nordahl, Wells and Hjemdal.
Références
Front Psychol. 2017 Jan 24;8:31
pubmed: 28174547
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
pubmed: 6080235
Behav Res Ther. 1996 Nov-Dec;34(11-12):881-8
pubmed: 8990539
Lancet Psychiatry. 2016 Feb;3(2):137-44
pubmed: 26777773
Acta Psychiatr Scand. 2004 May;109(5):339-44
pubmed: 15049770
Psychiatry Res. 2016 Aug 30;242:171-173
pubmed: 27285952
J Pers Assess. 1990 Winter;55(3-4):521-36
pubmed: 2280321
PLoS One. 2012;7(8):e42567
pubmed: 22905150
J Consult Clin Psychol. 1999 Jun;67(3):300-7
pubmed: 10369050
Curr Opin Psychiatry. 2015 Jan;28(1):24-9
pubmed: 25415495
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Front Psychol. 2019 Aug 08;10:1842
pubmed: 31440193
Arch Gen Psychiatry. 1992 Oct;49(10):782-7
pubmed: 1417430
Front Psychol. 2019 Aug 06;10:1714
pubmed: 31447722
Behav Res Ther. 2004 Apr;42(4):385-96
pubmed: 14998733
Behav Res Ther. 1990;28(6):487-95
pubmed: 2076086
Clin Psychol Rev. 2010 Mar;30(2):217-37
pubmed: 20015584
Behav Res Ther. 2012 Jun;50(6):367-73
pubmed: 22498310
Annu Rev Psychol. 2006;57:285-315
pubmed: 16318597
Front Psychol. 2018 Aug 07;9:1415
pubmed: 30131749
Front Psychol. 2018 Nov 14;9:2211
pubmed: 30487770
Arch Gen Psychiatry. 1991 Sep;48(9):851-5
pubmed: 1929776
J Consult Clin Psychol. 2007 Jun;75(3):475-88
pubmed: 17563164
Int J Epidemiol. 2014 Apr;43(2):318-29
pubmed: 24760873
J Pers Soc Psychol. 1991 Jul;61(1):115-21
pubmed: 1890582
Occup Environ Med. 2018 Oct;75(10):703-708
pubmed: 30032103
Clin Psychol Rev. 2006 Jan;26(1):17-31
pubmed: 16199119
Perspect Psychol Sci. 2008 Sep;3(5):400-24
pubmed: 26158958
Nord J Psychiatry. 2015 Feb;69(2):126-31
pubmed: 25124119